Daewoong Pharmaceutical acquires cGMP approval of Nabota factory from US FDA

Daewoong Pharmaceutical(CEO Seung-Ho Jeon) received an establishment inspection report(EIR) which mentioned approval for the Nabota(prabotulinumtoxin A, DWP-450) manufacturing facility from the US Food and Drug Administration(FDA). Thus, Daewoong Pharmaceutical is now prepared to acquire approval of Nabota, a self-developed botulinum toxin product, from the US FDA.

As part of the evaluation pr...